Overview
Autosomal dominant generalized dystrophic epidermolysis bullosa (ADDEB-G), also known as autosomal dominant dystrophic epidermolysis bullosa generalisata, is a hereditary skin fragility disorder belonging to the dystrophic epidermolysis bullosa (DEB) group. It is caused by heterozygous mutations in the COL7A1 gene, which encodes type VII collagen, a critical structural protein that forms anchoring fibrils at the dermal-epidermal junction. Deficiency or dysfunction of type VII collagen leads to impaired adhesion between the epidermis and dermis, resulting in skin blistering and erosions following minor mechanical trauma. The condition typically presents at birth or in early infancy with widespread (generalized) blistering of the skin. Key clinical features include skin fragility with blisters and erosions that heal with scarring, milia (small white cysts) formation, and dystrophic or absent nails. The blistering can affect the trunk, extremities, and sometimes mucosal surfaces including the oral cavity and esophagus, though mucosal involvement is generally less severe than in recessive forms of dystrophic EB. Over time, patients may develop hypertrophic or atrophic scarring. Compared to autosomal recessive dystrophic epidermolysis bullosa, the autosomal dominant generalized form tends to have a milder clinical course, though significant variability exists even within families carrying the same mutation. There is currently no cure for ADDEB-G. Management is primarily supportive and focuses on wound care, prevention of trauma and infection, pain management, and nutritional support. Careful wound dressing with non-adherent bandages is essential. Monitoring for complications such as esophageal strictures, dental abnormalities, and secondary skin infections is important. Emerging therapies including gene therapy, protein replacement therapy, and cell-based approaches are under investigation but remain largely experimental. Genetic counseling is recommended for affected individuals and their families.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Autosomal dominant generalized dystrophic epidermolysis bullosa.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal dominant generalized dystrophic epidermolysis bullosa at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Autosomal dominant generalized dystrophic epidermolysis bullosa.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal dominant generalized dystrophic epidermolysis bullosa.
Community
No community posts yet. Be the first to share your experience with Autosomal dominant generalized dystrophic epidermolysis bullosa.
Start the conversation →Latest news about Autosomal dominant generalized dystrophic epidermolysis bullosa
No recent news articles for Autosomal dominant generalized dystrophic epidermolysis bullosa.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Autosomal dominant generalized dystrophic epidermolysis bullosa
What is Autosomal dominant generalized dystrophic epidermolysis bullosa?
Autosomal dominant generalized dystrophic epidermolysis bullosa (ADDEB-G), also known as autosomal dominant dystrophic epidermolysis bullosa generalisata, is a hereditary skin fragility disorder belonging to the dystrophic epidermolysis bullosa (DEB) group. It is caused by heterozygous mutations in the COL7A1 gene, which encodes type VII collagen, a critical structural protein that forms anchoring fibrils at the dermal-epidermal junction. Deficiency or dysfunction of type VII collagen leads to impaired adhesion between the epidermis and dermis, resulting in skin blistering and erosions followi
How is Autosomal dominant generalized dystrophic epidermolysis bullosa inherited?
Autosomal dominant generalized dystrophic epidermolysis bullosa follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autosomal dominant generalized dystrophic epidermolysis bullosa typically begin?
Typical onset of Autosomal dominant generalized dystrophic epidermolysis bullosa is neonatal. Age of onset can vary across affected individuals.